Author response: Role of Lugol solution before total thyroidectomy for Graves’ disease: randomized clinical trial

After analysis of the research findings by Schiavone et al.1, we acknowledge the efficacy of Lugol’s solution in reducing FT3 and FT4 levels. However, the study also indicates that the preoperative use of Lugol’s solution did not significantly reduce intraoperative bleeding, the duration of surgery, or postoperative complications in patients with Graves’ disease undergoing total thyroidectomy. The study concludes that preoperative Lugol’s solution should not be considered mandatory for these patients. Nevertheless, we believe that there are several issues within the study that could impact on the accuracy of the results.